Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Matos, Ines ^a   Mizenina, Olga ^a   Lubkin, Ashira ^a   Steinman, Ralph M ^a   Idoyaga, Juliana ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LACK PROTEIN; LEIF PROTEIN; LEISHMANIA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PARASITE ANTIGEN; RECEPTOR PROTEIN; STRESS INDUCIBLE 1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROTOZOAL PROTEIN; TUMOR NECROSIS FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENETIC ENGINEERING; HAPLOTYPE; IMMUNE RESPONSE; IMMUNITY; IN VIVO STUDY; LEISHMANIA MAJOR; MOUSE; NONHUMAN; RECEPTOR AFFINITY; SKIN LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; IMMUNIZATION; IMMUNOLOGY; METABOLISM; PARASITOLOGY; TH1 CELL;

ANIMALIA; EUKARYOTA; LEISHMANIA MAJOR; MUS;

ANIMALS; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; IMMUNIZATION; INTERFERON-GAMMA; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTOZOAN PROTEINS; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879478989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067453     Document Type: Article

References (64)

1. Kaye P, Scott P, (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9: 604-615.
2. Tripathi P, Singh V, Naik S, (2007) Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 51: 229-242.
3. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
4. Scott P, Artis D, Uzonna J, Zaph C, (2004) The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201: 318-338.
5. Reiner SL, Locksley RM, (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151-177.
6. Launois P, Louis JA, Milon G, (1997) The fate and persistence of Leishmania major in mice of different genetic backgrounds: an example of exploitation of the immune system by intracellular parasites. Parasitology 115Suppl: S25-S32.
7. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, et al. (2003) Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170: 3171-3179.
8. Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, et al. (1995) Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). Vet Parasitol 60: 199-212.
9. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, et al. (2005) Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23: 3716-3725.
10. Sjolander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E, (1998) Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16: 2077-2084.
11. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, et al. (1995) Expression cloning of a protective Leishmania antigen. Science 268: 563-566.
12. Coler RN, Reed SG, (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
13. Murray HW, Berman JD, Davies CR, Saravia NG, (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
14. Steinman RM, (2007) Dendritic cells: versatile controllers of the immune system. Nat Med 13: 1155-1159.
15. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
16. Pulendran B, Palucka K, Banchereau J, (2001) Sensing pathogens and tuning immune responses. Science 293: 253-256.
17. Remer KA, Apetrei C, Schwarz T, Linden C, Moll H, (2007) Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur J Immunol 37: 2463-2473.
18. Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H, (2004) Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172: 6281-6289.
19. Flohe SB, Bauer C, Flohe S, Moll H, (1998) Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 28: 3800-3811.
20. Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, et al. (2007) A subset of dendritic cells induces CD4+ T cells to produce IFN-g by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med 204: 1095-1106.
21. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824.
22. Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, et al. (2006) Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 203: 607-617.
23. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, et al. (2012) Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 271: 183-192.
24. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, et al. (2011) Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 108: 2384-2389.
25. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, et al. (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105: 2574-2579.
26. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, et al. (2009) Dendritic cells require a systemic type I interferon response to induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602.
27. Do Y, Park CG, Kang YS, Park SH, Lynch RM, et al. (2008) Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol 38: 20-29.
28. Do Y, Didierlaurent AM, Ryu S, Koh H, Park CG, et al. (2012) Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine 30: 6359-6367.
29. Webb JR, Campos-Neto A, Skeiky YA, Reed SG, (1997) Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol Biochem Parasitol 89: 179-193.
30. Webb JR, Kaufmann D, Campos-Neto A, Reed SG, (1996) Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 157: 5034-5041.
31. Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, et al. (2002) Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 70: 2828-2836.
32. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, et al. (2002) Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70: 4215-4225.
33. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 4648-4654.
34. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, et al. (2009) Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329-337.
35. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
36. Macedo AB, Sanchez-Arcila JC, Schubach AO, Mendonca SC, Marins-Dos-Santos A, et al. (2012) Multifunctional CD4 T cells in patients with American cutaneous leishmaniasis. Clin Exp Immunol 167: 505-513.
37. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, et al. (2009) Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
38. Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, et al. (1998) LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 161: 6171-6179.
39. Launois P, Maillard I, Pingel S, Swihart KG, Xenarios I, et al. (1997) IL-4 rapidly produced by Vb4 Va8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6: 541-549.
40. Larregina AT, Falo LD Jr, (2005) Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol 124: 1-12.
41. Romani N, Thurnher M, Idoyaga J, Steinman RM, Flacher V, (2010) Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 88: 424-430.
42. Launois P, Tacchini-Cottier F, Kieny MP, (2008) Cutaneous leishmaniasis: progress towards a vaccine. Expert Rev Vaccines 7: 1277-1287.
43. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, et al. (2003) Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J Immunol 170: 5625-5629.
44. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, et al. (2012) Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 14: R39.
45. Hemmi H, Zaidi N, Wang B, Matos I, Fiorese C, et al. (2012) Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein. J Immunol 188: 1147-1155.
46. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, et al. (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69: 4103-4108.
47. Chakkalath HR, Theodos CM, Markowitz JS, Grusby MJ, Glimcher LH, et al. (1995) Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease. J Infect Dis 171: 1302-1308.
48. Gurunathan S, Prussin C, Sacks DL, Seder RA, (1998) Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4: 1409-1415.
49. Melby PC, Yang J, Zhao W, Perez LE, Cheng J, (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69: 4719-4725.
50. Skeiky YAW, Guderian JA, Benson DR, Bacelar O, Carvalho EM, et al. (1995) A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 181: 1527-1537.
51. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28: 6581-6587.
52. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, et al. (1997) In vivo microbial stimulation induces rapid CD40L-independent production of IL-12 by dendritic cells and their re-distribution to T cell areas. J Exp Med 186: 1819-1829.
53. Hochrein H, Shortman K, Vremec D, Scott B, Hertzog P, et al. (2001) Differential production of IL-12, IFN-a, and IFN-g by mouse dendritic cell subsets. J Immunol 166: 5448-5455.
54. Kastenmuller K, Espinosa DA, Trager L, Stoyanov C, Salazar AM, et al. (2013) Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I.C.) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect Immun 81: 789-800.
55. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, et al. (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208: 2357-2366.
56. Ponte-Sucre A, Heise D, Moll H, (2001) Leishmania major lipophosphoglycan modulates the phenotype and inhibits migration of murine Langerhans cells. Immunology 104: 462-467.
57. Mauel J, (1990) Macrophage-parasite interactions in Leishmania infections. J Leukoc Biol 47: 187-193.
58. Kraal G, Breel M, Janse M, Bruin G, (1986) Langerhans cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J Exp Med 163: 981-997.
59. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, et al. (1995) The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375: 151-155.
60. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-780.
61. Mossessova E, Lima CD, (2000) Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol Cell 5: 865-876.
62. Aida Y, Pabst MJ, (1990) Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132: 191-195.
63. Sacks DL, Hieny S, Sher A, (1985) Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J Immunol 135: 564-569.
64. Titus RG, Marchand M, Boon T, Louis JA, (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545-555.